B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia
Abstract
:1. Introduction
2. Methods and Materials
2.1. Patient Recruitment
2.2. Sample Collection
2.3. Hematological Analysis
2.4. Isolation of Peripheral Blood Mononuclear Cells (PBMCs)
2.5. T Cell Depletion and B Cell Isolation from Peripheral Blood Mononuclear Cells
2.6. Measurements of B Cell Subsets
2.7. Measurements of Immune Checkpoint Levels on B Cell Subsets
2.8. Measurements of Serum Soluble Beta-2 Microglobulin (B2M) Levels
2.9. Sample Size Estimation
2.10. Statistical Analysis
3. Results
3.1. Patient Characteristics and Hematological Parameters
3.2. Increased Levels of Activated B Cells in Patients with CLL
3.3. Elevated Levels of PD-1 Expression on Activated B Cells and Memory B Cells in Patients with CLL
3.4. Elevated Levels of CTLA-4 on Activated and Memory B Cells in Patients with CLL
3.5. Decreased Levels of PD-L2 Expression on Activated and Memory B Cells in Patients with CLL
3.6. Analysis of Immune Checkpoint (PD-1 and CTLA-4) Expression among B Cell Subsets in Patients with CLL
3.7. β2 Microglobulin Levels Are Not Associated with the Expression of PD-1 or CTLA-4 on B Cell Subsets
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- DeSantis, C.E.; Miller, K.D.; Dale, W.; Mohile, S.G.; Cohen, H.J.; Leach, C.R.; Sauer, A.G.; Jemal, A.; Siegel, R.L. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J. Clin. 2019, 69, 452–467. [Google Scholar] [CrossRef]
- Yang, S.; Varghese, A.M.; Sood, N.; Chiattone, C.; Akinola, N.O.; Huang, X.; Gale, R.P. Ethnic and geographic diversity of chronic lymphocytic leukaemia. Leukemia 2021, 35, 433–439. [Google Scholar] [CrossRef]
- Lanasa, M.C. Novel Insights into the Biology of CLL. Hematol. Am. Soc. Hematol. Educ. Program 2010, 2010, 70–76. [Google Scholar] [CrossRef]
- Gupta, S.L.; Khan, N.; Basu, S.; Soni, V. B-cell-based immunotherapy: A promising new alternative. Vaccines 2022, 10, 879. [Google Scholar] [CrossRef]
- Schwartz, M.; Zhang, Y.; Rosenblatt, J.D. B cell regulation of the anti-tumor response and role in carcinogenesis. J. Immunother. Cancer 2016, 4, 40. [Google Scholar] [CrossRef]
- Palma, M.; Gentilcore, G.; Heimersson, K.; Mozaffari, F.; Näsman-Glaser, B.; Young, E.; Rosenquist, R.; Hansson, L.; Österborg, A.; Mellstedt, H. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 2017, 102, 562–572. [Google Scholar] [CrossRef]
- Zhang, X.; Zhang, H.; Chen, L.; Feng, Z.; Gao, L.; Li, Q. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia. Cell. Immunol. 2019, 344, 103958. [Google Scholar] [CrossRef] [PubMed]
- Ding, W.; LaPlant, B.R.; Call, T.G.; Parikh, S.A.; Leis, J.F.; He, R.; Shanafelt, T.D.; Sinha, S.; Le-Rademacher, J.; Feldman, A.L.; et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 2017, 129, 3419–3427. [Google Scholar] [CrossRef] [PubMed]
- Brown, J.R.; Eichhorst, B.; Hillmen, P.; Jurczak, W.; Kaźmierczak, M.; Lamanna, N.; O’Brien, S.M.; Tam, C.S.; Qiu, L.; Zhou, K.; et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med. 2023, 388, 319–332. [Google Scholar] [CrossRef] [PubMed]
- Bo, M.D.; Bulian, P.; Bomben, R.; Zucchetto, A.; Rossi, F.M.; Pozzo, F.; Tissino, E.; Benedetti, D.; Bittolo, T.; Nanni, P.; et al. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia 2016, 30, 2011–2018. [Google Scholar]
- Wierda, W. New prognostic factors in chronic lymphocytic leukemia. Clin. Adv. Hematol. Oncol. 2009, 7, 32–33+42. [Google Scholar]
- Al-Rekabi, A.N.; Alwan, A.F.; Alobaidi, N.K. Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre-and posttherapy. Iraqi J. Hematol. 2020, 9, 155–159. [Google Scholar]
- Jaatinen, T.; Laine, J. Isolation of Mononuclear Cells from Human Cord Blood by Ficoll-Paque Density Gradient. Curr. Protoc. Stem Cell Biol. 2007, 1, 2A.1.1–2A.1.4. [Google Scholar] [CrossRef]
- Wei, Y.; Huang, C.-X.; Xiao, X.; Chen, D.-P.; Shan, H.; He, H.; Kuang, D.-M. B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments. Oncogene 2021, 40, 4737–4745. [Google Scholar] [CrossRef]
- Axelsson, S.; Magnuson, A.; Lange, A.; Alshamari, A.; Hörnquist, E.H.; Hultgren, O. A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex. BMC Immunol. 2020, 21, 14. [Google Scholar] [CrossRef]
- Joscelyn, J.; Ochoa-Repáraz, J.; Kasper, L. Principles of Immunotherapy; Clinical Neuroimmunology; Springer: Berlin/Heidelberg, Germany, 2020; pp. 17–42. [Google Scholar]
- Mkhwanazi, Z.A.; Nyambuya, T.M.; Mfusi, S.A.; Nkambule, B.B. Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: A systematic review and meta-analysis of prognostic factors. BMC Cancer 2022, 22, 1218. [Google Scholar] [CrossRef]
- R Core Team. A Language and Environment for Statistical Computing. 2021. Available online: https://www.r-project.org/ (accessed on 10 September 2023).
- Hallek, M.; Cheson, B.D.; Catovsky, D.; Caligaris-Cappio, F.; Dighiero, G.; Döhner, H.; Hillmen, P.; Keating, M.J.; Montserrat, E.; Rai, K.R.; et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood J. Am. Soc. Hematol. 2008, 111, 5446–5456. [Google Scholar] [CrossRef]
- Damle, R.N.; Temburni, S.; Calissano, C.; Yancopoulos, S.; Banapour, T.; Sison, C.; Allen, S.L.; Rai, K.R.; Chiorazzi, N. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007, 110, 3352–3359. [Google Scholar] [CrossRef]
- Gentile, M.; Morabito, F.; Del Poeta, G.; Mauro, F.R.; Reda, G.; Sportoletti, P.; Laurenti, L.; Coscia, M.; Herishanu, Y.; Recchia, A.G.; et al. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia 2021, 35, 235–238. [Google Scholar] [CrossRef]
- Amaya-Chanaga, C.I.; Rassenti, L.Z. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. Best Pract. Res. Clin. Haematol. 2016, 29, 79–89. [Google Scholar] [CrossRef]
- Soma, L.A.; Craig, F.E.; Swerdlow, S.H. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Human Pathol. 2006, 37, 152–159. [Google Scholar] [CrossRef]
- Khoudoleeva, O.; Gretsov, E.; Barteneva, N.; Vorobjev, I. Proliferative index and expression of CD38, Zap-70, and CD25 in different lymphoid compartments of chronic lymphocytic leukemia patients. Pathol. Lab. Med. Int. 2011, 3, 7–16. [Google Scholar]
- Patten, P.E.M.; Buggins, A.G.S.; Richards, J.; Wotherspoon, A.; Salisbury, J.; Mufti, G.J.; Hamblin, T.J.; Devereux, S. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008, 111, 5173–5181. [Google Scholar] [CrossRef]
- Rusak, M.; Eljaszewicz, A.; Bołkun, Ł.; Łuksza, E.; Łapuć, I.; Piszcz, J.; Singh, P.; Dąbrowska, M.; Bodzenta-Łukaszyk, A.; Kłoczko, J.; et al. Prognostic significance of PD-1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemia. Pol. Arch. Med. Wewn. 2015, 125, 553–559. [Google Scholar] [CrossRef]
- Hallek, M.; Shanafelt, T.D.; Eichhorst, B. Chronic lymphocytic leukaemia. Lancet 2018, 391, 1524–1537. [Google Scholar] [CrossRef]
- Forconi, F.; Moss, P. Perturbation of the normal immune system in patients with CLL. Blood 2015, 126, 573–581. [Google Scholar] [CrossRef]
- Yang, Y.; Li, X.; Ma, Z.; Wang, C.; Yang, Q.; Byrne-Steele, M.; Hong, R.; Min, Q.; Zhou, G.; Cheng, Y.; et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance. Nat. Commun. 2021, 12, 525. [Google Scholar] [CrossRef]
- Yamazaki, T.; Akiba, H.; Iwai, H.; Matsuda, H.; Aoki, M.; Tanno, Y.; Shin, T.; Tsuchiya, H.; Pardoll, D.M.; Okumura, K.; et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 2002, 169, 5538–5545. [Google Scholar] [CrossRef]
- Riley, J.L. PD-1 signaling in primary T cells. Immunol. Rev. 2009, 229, 114–125. [Google Scholar] [CrossRef]
- Lorenz, U. SHP-1 and SHP-2 in T cells: Two phosphatases functioning at many levels. Immunol. Rev. 2009, 228, 342–359. [Google Scholar] [CrossRef]
- Boussiotis, V.A.; Chatterjee, P.; Li, L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014, 20, 265. [Google Scholar] [CrossRef]
- Patsoukis, N.; Wang, Q.; Strauss, L.; Boussiotis, V.A. Revisiting the PD-1 pathway. Sci. Adv. 2020, 6, eabd2712. [Google Scholar] [CrossRef]
- Chemnitz, J.M.; Parry, R.V.; Nichols, K.E.; June, C.H.; Riley, J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 2004, 173, 945–954. [Google Scholar] [CrossRef]
- Thibult, M.-L.; Mamessier, E.; Gertner-Dardenne, J.; Pastor, S.; Just-Landi, S.; Xerri, L.; Chetaille, B.; Olive, D. PD-1 is a novel regulator of human B-cell activation. Int. Immunol. 2013, 25, 129–137. [Google Scholar] [CrossRef]
- Riches, J.C.; Davies, J.K.; McClanahan, F.; Fatah, R.; Iqbal, S.; Agrawal, S.; Ramsay, A.G.; Gribben, J.G. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013, 121, 1612–1621. [Google Scholar] [CrossRef]
- Ghiotto, M.; Gauthier, L.; Serriari, N.; Pastor, S.; Truneh, A.; Nunès, J.A.; Olive, D. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int. Immunol. 2010, 22, 651–660. [Google Scholar] [CrossRef]
- Linsley, P.S.; Wallace, P.M.; Johnson, J.; Gibson, M.G.; Greene, J.L.; Ledbetter, J.A.; Singh, C.; Tepper, M.A. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992, 257, 792–795. [Google Scholar] [CrossRef]
- Kosmaczewska, A.; Ciszak, L.; Suwalska, K.; Wolowiec, D.; Frydecka, I. CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia 2005, 19, 301–304. [Google Scholar] [CrossRef]
- Karabon, L.; Partyka, A.; Ciszak, L.; Pawlak-Adamska, E.; Tomkiewicz, A.; Bojarska-Junak, A.; Roliński, J.; Wołowiec, D.; Wrobel, T.; Frydecka, I.; et al. Abnormal expression of BTLA and CTLA-4 immune checkpoint molecules in chronic lymphocytic leukemia patients. J. Immunol. Res. 2020, 2020, 6545921. [Google Scholar] [CrossRef]
- Montillo, M.; Hamblin, T.; Hallek, M.; Montserrat, E.; Morra, E. Chronic lymphocytic leukemia: Novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005, 90, 391–399. [Google Scholar]
Control (n = 12) | Patients with CLL (n = 21) | p-Value | |
---|---|---|---|
Age (Years) | 56.58 ± 15.67 | 62.33 ± 13.31 | 0.2714 |
Male, n (%) | 58.33 | 61.9 | |
Female, n (%) | 41.67 | 38.1 | |
White blood cell count (103 µL) | 5.26 ± 1.38 | 130.4 ± 29.71 | 0.0005 |
Red blood cell (106 µL) | 4.74 ± 0.94 | 2.10 ± 0.84 | <0.0001 |
Hemoglobin (g/dL) | 14.13 ± 3.81 | 8.19 ± 2.30 | <0.0001 |
Platelets (103 µL) | 210.4 ± 73.14 | 157.5 ± 141.9 | 0.1831 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ntsethe, A.; Mkhwanazi, Z.A.; Dludla, P.V.; Nkambule, B.B. B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia. Curr. Issues Mol. Biol. 2024, 46, 1731-1740. https://doi.org/10.3390/cimb46030112
Ntsethe A, Mkhwanazi ZA, Dludla PV, Nkambule BB. B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia. Current Issues in Molecular Biology. 2024; 46(3):1731-1740. https://doi.org/10.3390/cimb46030112
Chicago/Turabian StyleNtsethe, Aviwe, Zekhethelo Alondwe Mkhwanazi, Phiwayinkosi Vusi Dludla, and Bongani Brian Nkambule. 2024. "B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia" Current Issues in Molecular Biology 46, no. 3: 1731-1740. https://doi.org/10.3390/cimb46030112